BGNE

BeiGene Share Price - BGNE

196.03
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
196.03
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
BeiGene Ltd BGNE NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-3.78 -1.89% 196.03 192.01 200.46 199.90 199.81 16:36:32
Bid Price Ask Price Spread Spread % News
192.01 198.55 6.54 3.29% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
3,408 211,598  196.18  41,510,583 230,128
Last Trade Time Type Quantity Stock Price Currency
16:32:43 priorref 175  196.03 USD

BeiGene Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 15.25B 77.78M 76.94M  428.21M  - -15.86 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News BeiGene

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

BGNE Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

BeiGene Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.


Your Recent History
NASDAQ
BGNE
BeiGene
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.